J Ethnopharmacol:结合网络药理学和转录组学验证研究木防己汤预防肺癌的疗效及机制

2022-08-14 紫菀款冬 MedSci原创

参照传统用法,探讨木防己汤预防肺癌的疗效和机制。

背景:《金匮要略》中著名的中药方剂木防己汤(MFJD),2000多年来在中国被用于治疗咳嗽、哮喘和缓解胸痛。中医使用MFJD治疗肺癌和癌性胸水,但MFJD对肺癌的预防作用及其潜在机制尚不明确

目的:参照传统用法,探讨MFJD预防肺癌的疗效和机制。

方法:采用肿瘤同种移植实验和宿主抗肿瘤实验,观察其直接抗肿瘤作用和间接抗肿瘤免疫作用,小鼠肺癌模型用于评价MFJD对肺癌的剂量反应和预防作用。

MFJD的活性成分通过UPLC-MS/MS获得。通过网络药理学和转录组学筛选MFJD的潜在靶点。通过蛋白质-蛋白质相互作用、分子对接和David数据库获得MFJD治疗肺癌的靶点和通路,并在体外和体内验证预测结果

结果:MFJD在宿主抗肿瘤实验中能显著抑制肿瘤生长,但在肿瘤同种移植实验中不能,表明其具有抗肿瘤免疫作用。在小鼠肺癌模型中,MFJD可通过剂量反应减少肺结节。

髓过氧化物酶(MPO)被选为核心靶点,因为其在蛋白质-蛋白质相互作用网络中具有最高的程度值,并且在分子对接中具有与防己碱和去氢木香内酯的潜在结合活性。

在体内,MPO表达的中性粒细胞与肺癌进展呈负相关,MFJD可促进中性粒细胞相关的免疫监测。在体外,防己碱和去氢木香内酯可以剂量依赖性地促进中性粒细胞吞噬、MPO和ROS的产生

通过UPLC-MS/MS、网络药理学和转录组学鉴定,来自MFJD的主要化合物调节36个肺癌预防靶点。David数据库显示,MFJD通过调节4个免疫相关生物过程和3个免疫相关通路在免疫调节中发挥重要作用。

结论:MFJD主要通过促进MPO表达以维持中性粒细胞免疫监测来预防肺癌,其关键化合物是防己碱和去氢木香内酯。

 

文献来源:

Gao F, Niu Y, Sun L, et al. Integrating network pharmacology and transcriptomic validation to investigate the efficacy and mechanism of Mufangji decoction preventing lung cancer [published online ahead of print, 2022 Jul 30]. J Ethnopharmacol. 2022;115573. doi:10.1016/j.jep.2022.115573

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
    2023-07-07 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
    2023-04-01 mjldent
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1787818, encodeId=9d401e87818b1, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Mar 25 23:53:59 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996501, encodeId=3766199650170, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Jul 07 06:53:59 CST 2023, time=2023-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788495, encodeId=0cd01e884956a, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Fri Aug 19 05:53:59 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908729, encodeId=0a411908e2916, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 18 08:53:59 CST 2023, time=2023-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747463, encodeId=a9a21e4746305, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Apr 01 04:53:59 CST 2023, time=2023-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420233, encodeId=225a1420233cc, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516200, encodeId=fabc1516200bc, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Wed Aug 10 15:53:59 CST 2022, time=2022-08-10, status=1, ipAttribution=)]

相关资讯

PNAS:正念冥想能够激活免疫反应,可用来防治免疫相关疾病

冥想作为一种行为干预的非药理学手段可以有效改善免疫反应,从而治疗各种与免疫系统紊乱相关的疾病。

Nature子刊:解锁新型通用同种异体CAR -T细胞免疫逃避新方法

这种方法的一个潜在优势是节省内源性免疫效应物,并允许它们与CAR- T细胞协同工作,以对抗难以治疗的癌症,包括实体瘤。

Nature:太狡猾!实体瘤欺骗一种T细胞抵御免疫攻击

科学家们可能有办法仅靶向那些被骗去保护肿瘤的Treg细胞,也许能让免疫系统的其他部分腾出手来发挥正常作用。

Cell:重磅!无论抗癌,还是抗感染,强大的免疫系统需要“镁”力!

这些发现在概念上将共刺激和营养感知联系了起来,并指出“镁-LFA-1”轴是一个治疗性的生物系统。

“网红”饮食法再登顶刊!Nature首度揭露:「间歇性禁食」竟可促进神经再生和修复

Nature:IF可增加肠道微生物的代谢物吲哚-3-丙酸(IPA),并利用免疫介导机制促进周围神经轴突的再生和功能修复。

生物制剂为什么效果这么好?一文搞懂TA在风湿免疫领域的应用

生物制剂主要用于治疗强直性脊柱炎、类风湿关节炎和系统性红斑狼疮等自身免疫性疾病,还可能导致神经系统不良反应,用药过程中仍然需要密切监测患者的肝功能、血常规等指标变化。